New agreement hands UK drugmaker control of developing jabs and provides cash injection for German group
Pharma group dealt another blow following decision by British to award vaccine contract to rival Pfizer
Brent Wisner, who won billions of dollars against Bayer, has received a big boost in Zantac cancer case
Litigation over Zantac is only one of several doubts the UK pharma group needs to overcome
Ruling means plaintiffs can present evidence alleging link between heartburn drug and cancer
Judge rules experts’ evidence admissible, leaving route open for 72,000 cancer sufferers to bring cases
Sale of 4.2% holding raises £1.25bn for pharmaceutical group as it shifts focus to high-value drugs
GSK joins UK government in committing £130mn to tackle growth of antimicrobial resistance
Quarterly results beat expectations and signal strong start for pharma group
Judge to decide on admission of evidence as part of litigation that has knocked billions off pharma group’s value
Group of 11 pharma, tech and luxury shares echoes US dominance of ‘Magnificent Seven’
Companies analysis from our sister publication
Strong uptake of UK pharma group’s vaccine has helped to ease fears of a patent cliff
Forerunners of pharma company tested vaccines at notorious institutions for decades
Shots will be given to children in Cameroon as part of rollout of up to 30mn jabs across continent
UK pharma group hopes acquisition of three-month start-up will broaden its range of asthma treatments
UK pharma group says country’s chemistry prowess makes it a good source of molecules
First jab for respiratory syncytial virus powers sales at UK drugmaker
UK drugmaker reaches agreement in US over cases tied to allegations heartburn medicine causes cancer
Agreement is first of its kind in China for UK-based pharma group
Accenture legal team wins FT award for its work on taking risks with confidence
Scientists hail ‘entirely novel approach’ to controlling a disease that kills more than 600,000 a year
Drugmaker does not specify reason but forex shortage has put pressure on multinationals
Drugmaker projects rise in revenue of up to 10% after consensus-beating second quarter
UK Edition
